Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$745.87
-0.6%
$752.67
$279.02
$830.21
$58.41B1.29587,068 shs373,385 shs
Morphic Holding, Inc. stock logo
MORF
Morphic
$56.99
$56.76
$19.34
$57.00
$2.85B1.491.27 million shs400 shs
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
$1.10
$1.08
$0.59
$8.08
$36.47M0.1701,788 shsN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
$644.67M0.01N/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.14
-3.0%
$1.27
$0.70
$2.44
$13.13M0.59160,799 shs31,798 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
+2.83%-6.47%-3.89%+29.71%+156.36%
Morphic Holding, Inc. stock logo
MORF
Morphic
0.00%0.00%0.00%0.00%+2.17%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-0.85%0.00%0.00%+12.50%-36.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.087 of 5 stars
2.43.00.00.04.12.50.0
Morphic Holding, Inc. stock logo
MORF
Morphic
0.9818 of 5 stars
1.00.00.04.80.03.30.0
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.4395 of 5 stars
0.02.00.00.03.30.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.77
Moderate Buy$716.36-3.96% Downside
Morphic Holding, Inc. stock logo
MORF
Morphic
2.00
Hold$57.000.02% Upside
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00
N/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest STSA, AXON, TXMD, MORF, and SVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$885.00
7/7/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/4/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$750.00 ➝ $895.00
5/14/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$730.00 ➝ $830.00
5/9/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$726.00 ➝ $735.00
5/8/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$600.00 ➝ $750.00
4/23/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$600.00 ➝ $600.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$2.08B27.88$2.77 per share269.30$30.52 per share24.44
Morphic Holding, Inc. stock logo
MORF
Morphic
$520K5,490.11N/AN/A$12.31 per share4.63
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$448.27M1.44$0.17 per share38.95$120.83 per share0.05
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.76M7.46N/AN/A$2.37 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$377.03M$4.14460.28223.9886.3614.86%5.81%2.83%8/5/2025 (Estimated)
Morphic Holding, Inc. stock logo
MORF
Morphic
-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$99.92MN/A0.00N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$2.18MN/A0.00N/A-114.07%-7.86%-5.46%8/11/2025 (Estimated)

Latest STSA, AXON, TXMD, MORF, and SVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.54N/AN/AN/A$641.77 millionN/A
5/13/2025Q1 2025
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A-$0.06N/A-$0.06N/A$0.39 million
5/7/2025Q1 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.34$1.41+$0.07$1.08$585.67 million$603.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
N/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
N/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A

Latest STSA, AXON, TXMD, MORF, and SVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
--$55.007/8/20255/23/20257/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
0.68
2.83
2.62
Morphic Holding, Inc. stock logo
MORF
Morphic
N/A
24.13
24.13
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/A
7.44
7.44
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
2.64
2.64

Institutional Ownership

CompanyInstitutional Ownership
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
79.08%
Morphic Holding, Inc. stock logo
MORF
Morphic
94.25%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
93.26%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
5.70%
Morphic Holding, Inc. stock logo
MORF
Morphic
25.60%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
31.20%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
12.79%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
4,97077.85 million73.41 millionOptionable
Morphic Holding, Inc. stock logo
MORF
Morphic
10050.09 million37.27 millionOptionable
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
2133.15 million22.81 millionNot Optionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,26199.64 million86.89 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.31 millionOptionable

Recent News About These Companies

TherapeuticsMD Shifts Focus with Lower Q3 Losses
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axon Enterprise stock logo

Axon Enterprise NASDAQ:AXON

$745.87 -4.39 (-0.59%)
As of 04:00 PM Eastern

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Morphic stock logo

Morphic NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Satsuma Pharmaceuticals stock logo

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$1.14 -0.04 (-2.99%)
Closing price 03:58 PM Eastern
Extended Trading
$1.13 -0.01 (-0.44%)
As of 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.